Fiche société
M.D. Anderson Cancer Center
Traitements, essais et publications liés.
Traitements52programmes
Essais30liés
Publications16liées
SourceDBlocale
Traitements
52| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ACT-Together (Acting on Cancer Testing-Together)To determine the feasibility of a group-based education intervention to improve adherence to recommend surveillance and risk reducing procedures, with a focus at medically underserved women and racial/ethnic minorities with BRCA 1 and 2. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New Paradigm for Acute Care Management of Cancer PatientsTo understand the experience of patients receiving care in the Care and Monitoring at Home program at MD Anderson. Researchers intend to use this information to study and possibly improve the hospital care at home program. | Cancer | À vérifier | À vérifier | United States | À vérifier |
| Bintrafusp AlfaThis phase I trial is to find out the best dose, possible benefits, and/or side effects of hypofractionated radiation therapy and bintrafusp alfa in treating patients with bile duct cancer that has spread to other places in the body (advanced intrahepatic cholangiocarcinoma). Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with bintrafusp alfa, a bifunctional fusion protein composed of the monoclonal antibody avelumab and TGF-beta, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The combination of hypofractionated radiation therapy and bintrafusp alfa may help to control intrahepatic cholangiocarcinoma. | Cancer | Phase 1 | United States | À vérifier | |
| BronchoscopyThis trial studies how well radial-probe endobronchial ultrasound works in detecting the complete or partial collapse of the lung in patients undergoing peripheral bronchoscopy. Diagnostic procedures, such as radial-probe endobronchial ultrasound and bronchoscopy, use a thin, tube-like instrument inserted through the nose or mouth to view and take pictures of the inside of the trachea, air passages, and lungs. | Cancer | À vérifier | À vérifier | United States | À vérifier |
| CryoablationThe FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality. | Cancer | Non applicable | Ablation tumorale non thermique | United States | Dispositif/procédure : résultats à interpréter par essai et indication. |
| Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients With Advanced CancerTo learn more about the experience and wellbeing of people who provide care for cancer patients. | Cancer | À vérifier | À vérifier | United States | À vérifier |
| DiscussionThis clinical trial evaluates the feasibility of exercise during chemotherapy in older women with stage I-III breast cancer. Previous studies have reported that exercise may reduce the chemotherapy-toxicity risk. This trial may help researchers learn if engaging in a physical activity program is feasible in patients receiving chemotherapy for breast cancer. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Edetate Calcium DisodiumThis phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| Enasidenib MesylateThis phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| EncorafenibThe purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encorafenib and binimetinib can continue until their melanoma is no longer responding. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| endorectal coiMultiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-csPCa. Furthermore, there is evidence that MRI is more accurate in detecting high-grade (Gleason grade group ≥3) versus low grade cancers (Gleason grade group \<2) and therefore may serve as a useful adjunct to prostate-specific antigen (PSA) testing, digital rectal examination, and prostatic biopsy to detect cancers that require definitive treatment as opposed to active surveillance. Many investigators, including our group, have shown the utility of preoperative mpMRI to assess the local extent of prostate cancer and for surgical planning. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Evaluation of Hereditary Cancer Educational VideosTo learn if educational videos can help participants be more informed about hereditary cancers (ones that run in the family). | Cancer | À vérifier | À vérifier | United States | À vérifier |
| Expressive Writing for the Management of Stress in Cancer SurvivorsThis clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduced social interaction with family and friends. Together with the economic uncertainties that come with this pandemic, these factors are likely to increase cancer survivors' stress levels. Expressive writing may provide a medium through which cancer survivors confront stressors and find meaning in their experience. The goal of this trial is to learn more about the experiences of cancer survivors during stressful times. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Feasibility of Combined Genomics/Transcriptomics for Patients With LymphomaTo learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| flexible AIR coilMultiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-csPCa. Furthermore, there is evidence that MRI is more accurate in detecting high-grade (Gleason grade group ≥3) versus low grade cancers (Gleason grade group \<2) and therefore may serve as a useful adjunct to prostate-specific antigen (PSA) testing, digital rectal examination, and prostatic biopsy to detect cancers that require definitive treatment as opposed to active surveillance. Many investigators, including our group, have shown the utility of preoperative mpMRI to assess the local extent of prostate cancer and for surgical planning. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| fludarabine phosphateBackground: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes. Objective: To test the use of neoepitope-specific T cells in people with blood cancers Eligibility: People aged 18 to 75 years with any of 9 blood cancers. Design: Participants will have a bone marrow biopsy: A sample of soft tissue will be removed from inside a pelvic bone. This is needed to confirm their diagnosis and the TP53 and RAS mutations in their cancer cells. They will also have a skin biopsy to look for these mutations in other tissue. Participants will undergo apheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The T cells will be grown to become neoepitope-specific T cells. Participants receive drugs for 3 days to prepare their body for the treatment. The modified T cells will be given through a tube inserted into a vein. Participants will need to remain in the clinic at least 7 days after treatment. Participants will have 8 follow-up visits in the first year after treatment. They will have 6 more visits over the next 4 years. Long-term follow-up will go on for 10 more years. | Cancer, Lupus, SEP | Phase 1/2 | Immunomodulation | United States | À vérifier |
| Hyperpolarized 13-C-pyruvateTo learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| IdarubicinThis phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine, cytarabine, filgrastim and idarubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with combination chemotherapy may work better in treating patients with acute myeloid leukemia. | Cancer | Phase 1/2 | À vérifier | United States | À vérifier |
| Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic CancerThe study investigates whether certain characteristics of gynecological cancer can help researchers predict how well a patient recovers from surgery to remove the lower colon, rectum, and bladder, and create openings through which urine and stool are passed out of the body (pelvic exenteration). Comparing the types of surgery completed and procedures used may help researchers to determine which are most effective and safe in patients with a history of gynecologic cancer. | Cancer | À vérifier | Traitement symptomatique | United States | À vérifier |
| MethotrexateThis is a prospective, open-label, multicenter, randomized controlled study in treatment-naive patients with primary central nervous system lymphoma (PCNSL, DLBCL type). Eligible participants are randomized 1:1 to the experimental arm (R-MA-PD-1: rituximab, methotrexate, cytarabine plus penpulimab) or the control arm (R-MA: rituximab, methotrexate, cytarabine). Induction is administered every 21 days for 6 cycles, followed by risk- and response-adapted consolidation (ASCT or whole-brain radiotherapy) and penpulimab maintenance. The primary objective is to compare the 2-year progression-free survival rate between the two arms. | Cancer, SEP | Phase 2 | Ralentissement de la progression | United States | À vérifier |
| NBTXR3This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection. | Cancer | Phase 1/2 | À vérifier | United States | À vérifier |
| Oral CladribineThe goal of Part 1 of this clinical research study is to find the highest tolerable dose of cladribine that can be given in combination with low dose cytarabine (LDAC) and venetoclax to patients who have AML. The goal of Part 2 of this clinical research study is to learn if the dose of cladribine found in Part 1, when combined with LDAC and venetoclax, can help to control the disease. | Cancer | Phase 1/2 | À vérifier | United States | À vérifier |
| PEG-l-asparaginaseThis goal of this clinical research study is to learn if the combination of methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients) can help to control ALL that has not responded to previous treatment or has come back after a response or chronic myeloid leukemia (CML). | SEP | Phase 2 | À vérifier | United States | À vérifier |
| PegfilgrastimThis phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine, cytarabine, filgrastim and idarubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with combination chemotherapy may work better in treating patients with acute myeloid leukemia. | Cancer | Phase 1/2 | À vérifier | United States | À vérifier |
| Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family CaregiversThe goal of this behavioral research study is to learn about the effects of two different supportive care programs on patients' and their family caregivers' psychological wellbeing and overall quality of life. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Radial Probe Endobronchial UltrasoundThis trial studies how well radial-probe endobronchial ultrasound works in detecting the complete or partial collapse of the lung in patients undergoing peripheral bronchoscopy. Diagnostic procedures, such as radial-probe endobronchial ultrasound and bronchoscopy, use a thin, tube-like instrument inserted through the nose or mouth to view and take pictures of the inside of the trachea, air passages, and lungs. | Cancer | À vérifier | À vérifier | United States | À vérifier |
| SuccimerThis phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| TafasitamabThis phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tafasitamab is a monoclonal antibody that binds to CD19 antigen which is found on the surface of most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab with acalabrutinib and venetoclax may be safe and effective for treating patients with CLL/SLL. | Cancer, Lupus, SEP | Phase 1/2 | Immunomodulation | United States | À vérifier |
| Tafasitamab and NK cellsThe goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease. | Lupus | Phase 1/2 | À vérifier | United States | À vérifier |
| Therapeutic Conventional SurgeryThis pilot phase I/II trial studies the side effects and how well nivolumab and ipilimumab in combination with chemotherapy and radiation therapy work in treating patients with gastric cancer that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Intensity-modulated radiation therapy uses thin beams of radiation of different strengths aimed at the tumor from many angles. This type of radiation therapy may reduce the damage to healthy tissue near the tumor. Giving nivolumab, ipilimumab, chemotherapy and radiation therapy may work better in treating patients with gastric cancer. | Cancer | Phase 2 | United States | À vérifier | |
| UlixertinibTo find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| BronchoscopyThis trial studies how well radial-probe endobronchial ultrasound works in detecting the complete or partial collapse of the lung in patients undergoing peripheral bronchoscopy. Diagnostic procedures, such as radial-probe endobronchial ultrasound and bronchoscopy, use a thin, tube-like instrument inserted through the nose or mouth to view and take pictures of the inside of the trachea, air passages, and lungs. | Cancer | À vérifier | À vérifier | United States | À vérifier |
| Hyperpolarized 13-C-pyruvateTo learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family CaregiversThe goal of this behavioral research study is to learn about the effects of two different supportive care programs on patients' and their family caregivers' psychological wellbeing and overall quality of life. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients With Advanced CancerTo learn more about the experience and wellbeing of people who provide care for cancer patients. | Cancer | À vérifier | À vérifier | United States | À vérifier |
| An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New Paradigm for Acute Care Management of Cancer PatientsTo understand the experience of patients receiving care in the Care and Monitoring at Home program at MD Anderson. Researchers intend to use this information to study and possibly improve the hospital care at home program. | Cancer | À vérifier | À vérifier | United States | À vérifier |
| DiscussionThis clinical trial evaluates the feasibility of exercise during chemotherapy in older women with stage I-III breast cancer. Previous studies have reported that exercise may reduce the chemotherapy-toxicity risk. This trial may help researchers learn if engaging in a physical activity program is feasible in patients receiving chemotherapy for breast cancer. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Evaluation of Hereditary Cancer Educational VideosTo learn if educational videos can help participants be more informed about hereditary cancers (ones that run in the family). | Cancer | À vérifier | À vérifier | United States | À vérifier |
| Feasibility of Combined Genomics/Transcriptomics for Patients With LymphomaTo learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| flexible AIR coilMultiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-csPCa. Furthermore, there is evidence that MRI is more accurate in detecting high-grade (Gleason grade group ≥3) versus low grade cancers (Gleason grade group \<2) and therefore may serve as a useful adjunct to prostate-specific antigen (PSA) testing, digital rectal examination, and prostatic biopsy to detect cancers that require definitive treatment as opposed to active surveillance. Many investigators, including our group, have shown the utility of preoperative mpMRI to assess the local extent of prostate cancer and for surgical planning. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Expressive Writing for the Management of Stress in Cancer SurvivorsThis clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduced social interaction with family and friends. Together with the economic uncertainties that come with this pandemic, these factors are likely to increase cancer survivors' stress levels. Expressive writing may provide a medium through which cancer survivors confront stressors and find meaning in their experience. The goal of this trial is to learn more about the experiences of cancer survivors during stressful times. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| EncorafenibThe purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encorafenib and binimetinib can continue until their melanoma is no longer responding. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic. | Cancer | Phase 3 | À vérifier | United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Mexico, New Zealand, Norway, Poland, Russia, … | À vérifier |
| CryoablationThe FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality. | Cancer | Non applicable | Ablation tumorale non thermique | United States | Dispositif/procédure : résultats à interpréter par essai et indication. |
| Bintrafusp AlfaThis phase I trial is to find out the best dose, possible benefits, and/or side effects of hypofractionated radiation therapy and bintrafusp alfa in treating patients with bile duct cancer that has spread to other places in the body (advanced intrahepatic cholangiocarcinoma). Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with bintrafusp alfa, a bifunctional fusion protein composed of the monoclonal antibody avelumab and TGF-beta, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The combination of hypofractionated radiation therapy and bintrafusp alfa may help to control intrahepatic cholangiocarcinoma. | Cancer | Phase 1 | United States | À vérifier | |
| Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic CancerThe study investigates whether certain characteristics of gynecological cancer can help researchers predict how well a patient recovers from surgery to remove the lower colon, rectum, and bladder, and create openings through which urine and stool are passed out of the body (pelvic exenteration). Comparing the types of surgery completed and procedures used may help researchers to determine which are most effective and safe in patients with a history of gynecologic cancer. | Cancer | À vérifier | Traitement symptomatique | United States | À vérifier |
| ACT-Together (Acting on Cancer Testing-Together)To determine the feasibility of a group-based education intervention to improve adherence to recommend surveillance and risk reducing procedures, with a focus at medically underserved women and racial/ethnic minorities with BRCA 1 and 2. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| NBTXR3This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection. | Cancer | Phase 1/2 | À vérifier | United States | À vérifier |
| Edetate Calcium DisodiumThis phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| TafasitamabThis phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tafasitamab is a monoclonal antibody that binds to CD19 antigen which is found on the surface of most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab with acalabrutinib and venetoclax may be safe and effective for treating patients with CLL/SLL. | Lupus | Phase 1/2 | Immunomodulation | United States | À vérifier |
| MethotrexateThis is a prospective, open-label, multicenter, randomized controlled study in treatment-naive patients with primary central nervous system lymphoma (PCNSL, DLBCL type). Eligible participants are randomized 1:1 to the experimental arm (R-MA-PD-1: rituximab, methotrexate, cytarabine plus penpulimab) or the control arm (R-MA: rituximab, methotrexate, cytarabine). Induction is administered every 21 days for 6 cycles, followed by risk- and response-adapted consolidation (ASCT or whole-brain radiotherapy) and penpulimab maintenance. The primary objective is to compare the 2-year progression-free survival rate between the two arms. | SEP | Phase 2 | Ralentissement de la progression | United States | À vérifier |
| CryoablationThe FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality. | Cancer | Phase 3 | Ablation tumorale non thermique | Brazil | Dispositif/procédure : résultats à interpréter par essai et indication. |
| CryoablationThe FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality. | Cancer | Non applicable | Ablation tumorale non thermique | United States | Dispositif/procédure : résultats à interpréter par essai et indication. |
Essais cliniques
30| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Acalabrutinib | SEP | Phase 2 | NCT04169737 | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | RECRUITING |
| Cryoablation | Cancer | Non applicable | NCT00877682 | Prostate Conformal Cryotherapy | COMPLETED |
| Cryoablation | Cancer | Phase 3 | NCT06839001 | CRYSTAL - SIX — CRYoablation for Small Tumors As Local Treatment - SIX Trial | RECRUITING |
| Cyclophosphamide | SEP | Phase 2 | NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING |
| Methotrexate | SEP | Phase 2 | NCT00905034 | Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage | COMPLETED |
| Tafasitamab | Lupus | Phase 1/2 | NCT06434363 | Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders | RECRUITING |
| Biospecimen Collection | Cancer | Non applicable | NCT07377006 | Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer | RECRUITING |
| fluorouracil | Cancer | Phase 2 | NCT03776487 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | ACTIVE_NOT_RECRUITING |
| Edetate Calcium Disodium | Cancer | Phase 1 | NCT03630991 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | RECRUITING |
| NBTXR3 | Cancer | Phase 1/2 | NCT07224152 | NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer | RECRUITING |
| ACT-Together (Acting on Cancer Testing-Together) | Cancer | Non applicable | NCT06549153 | ACT-Together (Acting on Cancer Testing-Together) | ACTIVE_NOT_RECRUITING |
| Cytarabine | Cancer | Phase 1/2 | NCT03214562 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | RECRUITING |
| Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer | Cancer | À vérifier | NCT00791635 | Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer | ACTIVE_NOT_RECRUITING |
| Bintrafusp Alfa | Cancer | Phase 1 | NCT04708067 | Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | ACTIVE_NOT_RECRUITING |
| Azacitidine | Cancer | Phase 2 | NCT03683433 | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | RECRUITING |
| Cetuximab | Cancer | Phase 1 | NCT05985954 | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | RECRUITING |
| Cryoablation | Cancer | Non applicable | NCT07629206 | Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial) | RECRUITING |
| Psilocybin | Cancer | Phase 2 | NCT06200155 | Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | RECRUITING |
| Encorafenib | Cancer | Phase 3 | NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | ACTIVE_NOT_RECRUITING |
| Expressive Writing for the Management of Stress in Cancer Survivors | Cancer | Non applicable | NCT04776941 | Expressive Writing for the Management of Stress in Cancer Survivors | RECRUITING |
| flexible AIR coil | Cancer | Non applicable | NCT05043012 | Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study) | RECRUITING |
| Cytarabine | Cancer | Phase 1/2 | NCT07053020 | A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) | NOT_YET_RECRUITING |
| Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma | Cancer | Non applicable | NCT05464823 | Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma | ACTIVE_NOT_RECRUITING |
| Evaluation of Hereditary Cancer Educational Videos | Cancer | À vérifier | NCT06157801 | Evaluation of Hereditary Cancer Educational Videos | ACTIVE_NOT_RECRUITING |
| Discussion | Cancer | Non applicable | NCT05025059 | Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer | ACTIVE_NOT_RECRUITING |
| An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New Paradigm for Acute Care Management of Cancer Patients | Cancer | À vérifier | NCT05904899 | An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New Paradigm for Acute Care Management of Cancer Patients | SUSPENDED |
| Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients With Advanced Cancer | Cancer | À vérifier | NCT05904782 | Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients With Advanced Cancer | RECRUITING |
| Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers | Cancer | Non applicable | NCT06409065 | Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers | RECRUITING |
| Hyperpolarized 13-C-pyruvate | Cancer | Phase 1 | NCT05873699 | Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection | SUSPENDED |
| Bronchoscopy | Cancer | À vérifier | NCT03523689 | Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy | COMPLETED |
Publications
16| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Hyperpolarized 13-C-pyruvate | Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1- C]pyruvate MRI. | Abdominal radiology (New York) | ||
| Hyperpolarized 13-C-pyruvate | Imaging post-reperfusion metabolism in porcine myocardial infarction with hyperpolarized C pyruvate MRI. | Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance | ||
| Hyperpolarized 13-C-pyruvate | Repeatability of Metabolic Imaging With Hyperpolarized Pyruvate: Back-to-Back Neuroimaging and Blood Analysis. | Magnetic resonance in medicine | ||
| fludarabine phosphate | Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene. | Cancer research | ||
| fludarabine phosphate | In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. | Cancer chemotherapy and pharmacology | ||
| fludarabine phosphate | Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors. | Current pharmaceutical design | ||
| Radial Probe Endobronchial Ultrasound | 3D computed tomography airway geometry for predicting bronchoscopic accessibility in peripheral pulmonary nodules: a prospective study. | Translational lung cancer research | ||
| Bronchoscopy | Remimazolam for sedation in flexible bronchoscopy: A systematic review and meta-analysis of randomised controlled trials. | Pulmonology | ||
| Bronchoscopy | Landscape of the upper and lower airway microbiota in children with community-acquired pneumonia. | Virulence | ||
| Bronchoscopy | A multimodal bronchoscopic approach for diagnosing peripheral ground-glass nodules using Cone-Beam computed tomography and cryobiopsy: a preliminary study. | Annals of medicine | ||
| Bronchoscopy | Risk of Early Deterioration in Emergency Department Patients Presenting with Non-Massive Hemoptysis: A Prospective Cohort Study. | Journal of clinical medicine | ||
| Bronchoscopy | Bronchoscopy-Guided Intratracheal Suture Repair of Recurrent Tracheoesophageal Fistula in an Adolescent. | Journal of clinical medicine | ||
| Radial Probe Endobronchial Ultrasound | Diagnostic Yield and Safety of Radial Probe Endobronchial Ultrasound-Guided Transbronchial Lung Cryobiopsy with a Guide Sheath in Pulmonary Lesions < 3 cm. | Diagnostics (Basel, Switzerland) | ||
| Radial Probe Endobronchial Ultrasound | Advancing Transbronchial Lung Cryobiopsy in Interstitial Lung Disease with Adjunctive Tools and Smaller Cryoprobes. | Journal of clinical medicine | ||
| Bronchoscopy | Alternative to invasive bronchoscopy: validating tracheal aspirates for microbiome profiling in intensive care unit pneumonia patients. | Scientific reports | ||
| Bronchoscopy | Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD). | Arthritis research & therapy |